DSE : RENWICKJA
Renwick, Jajneswar & Co. (Bd) Ltd. — Key statistics
Drugs, Drug Proprietaries, and Druggists' Sundries · Bangladesh
Last price 799 BDT (At close: Oct 29, 2026) · Market cap 1.60B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Technical report: trend, RSI, support and resistance, charts
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.60B |
| Enterprise Value | 1.72B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.00M |
| Shares Outstanding | 2.00M |
| Shares Change (YoY) | -0.04% |
| Shares Change (QoQ) | -0.31% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 980,000 |
Ratios
| Measure | Value |
|---|
| PE Ratio | 1,119.31 |
| Forward PE | n/a |
| PS Ratio | 19.73 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 1,201.58 |
| EV / Sales | 21.18 |
| EV / EBITDA | 286.93 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.63 |
| Quick Ratio | 0.32 |
| Debt / Equity | n/a |
| Debt / EBITDA | 21.29 |
| Debt / FCF | n/a |
| Interest Coverage | 0.76 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 0.35% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -1.82% |
| Weighted Average Cost of Capital (WACC) | 3.40% |
| Revenue Per Employee | 880,277 |
| Profits Per Employee | 15,517 |
| Employee Count | 92 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 0.43 |
Taxes
| Measure | Value |
|---|
| Income Tax | 2.06M |
| Effective Tax Rate | 59.09% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.12 |
| 52-Week Price Change | +48.46% |
| 50-Day Moving Average | 764.19 |
| 200-Day Moving Average | 623.50 |
| Relative Strength Index (RSI) | 52.81 |
| Average Volume (20 Days) | 9,079 |
Shortselling
| Measure | Value |
|---|
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Incomestatement
| Measure | Value |
|---|
| Revenue | 80.99M |
| Gross Profit | 32.73M |
| Operating Income | 1.77M |
| Pretax Income | 3.49M |
| Net Income | 1.43M |
| EBITDA | 5.98M |
| EBIT | 1.77M |
| Earnings Per Share (EPS) | 0.71 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 9.95M |
| Total Debt | 127.28M |
| Net Cash | -117.32M |
| Net Cash Per Share | -58.66 |
| Equity (Book Value) | -225.46M |
| Book Value Per Share | -112.73 |
| Working Capital | -152.00M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -47.89M |
| Capital Expenditures | -6.46M |
| Depreciation & Amortization | 4.21M |
| Net Borrowing | 45.48M |
| Free Cash Flow | -54.35M |
| FCF Per Share | -27.18 |
Margins
| Measure | Value |
|---|
| Gross Margin | 40.41% |
| Operating Margin | 2.18% |
| Pretax Margin | 4.31% |
| Profit Margin | 1.76% |
| EBITDA Margin | 7.38% |
| EBIT Margin | 2.18% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.04% |
| Shareholder Yield | 0.04% |
| Earnings Yield | 0.09% |
| FCF Yield | -3.40% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Dec 4, 2011 |
| Split Type | Forward |
| Split Ratio | 10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.64 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | n/a |
| Graham Upside | n/a |